> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-69/
- Published: 2022-04-03T12:00:00.000Z
- Updated: 2026-09-14T17:39:07.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5133892

**Millenium Health** says it has won a contract worth a potential $1.6 million to provide FDA with urine drug tests for a trial that will assess the development of opioid tolerance in patients taking pain medication with an abuse deterrent formula. The company adds that it has recently agreed to a $256 million settlement of fraud charges under the Federal False Claims Act, in which the company was accused of charging Medicare, Medicaid and other federal health care programs for a large number of medically unnecessary urine drug and genetic tests.

**Boston Children’s Hospital’s** simulator program, SIMPeds is partnering with a special effects company **Fractured FX** to create ultra-realistic models of patients’ anatomy for surgical and medical training. According to the hospital, the simulators will allow clinicians to practice and rehearse difficult or complex medical procedures without any risk to patients. The hospital says the models incorporate artificial tissues that bleed and pulsate, manmade blood vessels that feel like the real thing when doctors insert a catheter and special gels that feel like brain tissue when an endoscope is guided through them.

**Eisai** subsidiary, **Morphotek**, has entered into a license agreement with Seattle-based **Blaze Bioscience** under which Morphotek will provide to Blaze a license to develop, license, and once approved, commercialize a potential tumor-targeting chlorotoxin derivative linked to a near-infrared diagnostic agent, which may help visualize cancer cells during surgery. The company says the derivative was originally isolated from scorpion venom. It adds that a completed Phase 2 clinical trial of radio-labeled chlorotoxin peptide evaluated overall survival in patients with recurrent glioma.

**Kator,** a medical device company currently operated by **Surgical Frontiers**, says that the U.S. Patent and Trademark Office has recently granted the company a patent related to its suture anchor technology. The patent covers a novel suture anchor device that eliminates the need for knot tying and locks different portions of a suture to different portions of the anchor, which enables much stronger surgical repair constructs than currently marketed suture anchors and enabling surgeons to achieve stronger tissue-to-bone repairs with fewer suture anchors, according to the company.

**GlaxoSmithKline** and **Merck** have begun a Phase 1 clinical trial designed to evaluate GSK’s investigational immunotherapy GSK3174998 as a monotherapy and in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab) in patients with locally advanced, recurrent or metastatic solid tumors that have progressed after standard treatment.